Treatment With Dual and Triple Therapy in Chronic Obstructive Pulmonary Disease in Line With Current Guidelines Reduces the Carbon Footprint
Author(s)
Janson C1, Hernando Platz J2, Soulard S3, Langham S4, Nicholson L5, Hartgers-Gubbels ES2
1Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 2Boehringer Ingelheim GmbH, Ingelheim Am Rhein, Germany, 3Boehringer Ingelheim MIDI, Amsterdam, Netherlands, 4Maverex Ltd, Manchester, UK, 5Maverex Ltd, Newcastle upon Tyne, UK
Presentation Documents
OBJECTIVES: International guidelines recommend triple therapy with long-acting antimuscarinic antagonists (LAMA), long-acting β-agonists (LABA), and inhaled corticosteroids only for patients with chronic obstructive pulmonary disease (COPD) who continue to exacerbate despite treatment with dual therapy. In clinical practice, triple therapy is often overprescribed. Further, inhaler device choice can also have a large impact on carbon footprint. This study aimed to assess the carbon footprint of hypothetically redistributing COPD patients, in line with international guidelines, on triple fixed dose combination (FDC) to LAMA/LABA soft-mist inhalers (SMI; Respimat® Spiolto).
METHODS: A model was established to assess the carbon footprint of redistributing triple therapy FDC to LAMA/LABA SMI (Respimat®) reusable in 12 European countries or disposable in the United States over 5 years. Inhaler use per country was derived from international prescribing data and CO2 emissions from published sources. The proportion of patients overprescribed according to international guidelines was based on UK data (Vioix et al, 2020; Value Heal. Dec 1;23:S719) and applied to all European countries, or unpublished data from the United States.
RESULTS: In Europe, 50% of patients and 92% in the United States were assumed to be prescribed triple therapy FDC not in line with international recommendations (this difference in proportions is attributable to the data being based on different sources). Over 5 years, hypothetical redistribution of triple therapy FDC to SMI (Respimat®) reusable reduced CO2 emissions by 70.7–98.4%. In the United States, redistribution to SMI (Respimat®) disposable reduced CO2 emissions by 16.1%. Across all countries, CO2 emissions were reduced by 143.7 kilo tonnes over 5 years, which is the equivalent of the annual carbon footprint of 21,447 EU citizens.
CONCLUSIONS: Prescribing SMI (Respimat®) dual therapy rather than triple therapy, where indicated, addresses both its inappropriate use, as well as reducing the carbon footprint.
Conference/Value in Health Info
Value in Health, Volume 25, Issue 12S (December 2022)
Code
HSD1
Disease
No Additional Disease & Conditions/Specialized Treatment Areas